SCHEMBL20817841

SCHEMBL20817841

CC(C)(C)[S+]([O-])N=Cc1cc(F)c(Cl)cc1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20791175 1.00
SCHEMBL20791159 1.00
SCHEMBL20791161 1.00
SCHEMBL20791177 1.00
SCHEMBL20791157 1.00
SCHEMBL20238070 0.86 GPR3 (0.31)
SCHEMBL20238074 0.86 GPR3 (0.31)
SCHEMBL20238073 0.86 GPR3 (0.31)
SCHEMBL28740524 0.86 GPR3 (0.31)
SCHEMBL19614299 0.83 KDM4E (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111601798-B Bisamide sarcomere activating compounds and uses thereof 美国安进公司 2023-08-11 CN disclosed
CN-111601798-A Bisamide sarcomere activating compound and use thereof 美国安进公司 2020-08-28 CN disclosed
EP-3681882-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF Amgen Inc. (US) 2020-07-22 EP disclosed
WO-2019055590-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. (US) 2019-03-21 WO disclosed